Tag: merger

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Logan Ridge Finance Corporation (NASDAQ: LRFC) (“Logan Ridge” or “LRFC”) announced today that it obtained shareholder approval for the merger of LRFC with and into Portman Ridge Finance Corporation (NASDAQ: PTMN) (“Portman Ridge” or “PTMN”) following the special meeting of shareholders held on June 20, 2025.

Stockholders of PTMN Who Have Voted Thus Far Have Expressed Strong Support for the Proposed Merger, with Favorability in Excess of 85%

Phoenix, AZ, June 20, 2025 (GLOBE NEWSWIRE) -- InnSuites Hospitality Trust (NYSE American: IHT) reported Hotel Revenue results surpassing $2 million once again in the First Fiscal Quarter of 2026, (February 1, 2025, to April 30, 2025), with Total Revenue of approximately $2.2 million.

New York, New York, June 20, 2025 (GLOBE NEWSWIRE) -- Axiom Intelligence Acquisition Corp 1 (NASDAQ:AXINU) (the “Company”) today announced the closing of its initial public offering of 20,000,000 units, which includes 2,500,000 units sold pursuant to the partial exercise of the underwriters’ over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $200,000,000.

BROOKLYN, N.Y., June 20, 2025 (GLOBE NEWSWIRE) -- Pioneer Acquisition I Corp (Nasdaq: PACHU) (the “Company”) today announced that it closed its initial public offering of 25,300,000 units at $10.00 per unit, including the issuance of 3,300,000 units as result of the underwriters’ exercise of its over-allotment option in full. The gross proceeds from the offering were $253 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “PACHU” on June 18, 2025.

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”).

 Virbac announces the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025.